The role of strontium-89 systemic radiotherapy in the management of osseous metastases from prostate cancer.
Strontium-89 systemic radiotherapy can play a significant role in the palliation of symptomatic osseous metastases from prostate cancer. Given as a single injection, strontium's affinity for osteoblastic activity draws it to all sites of osseous involvement simultaneously. The metastases are bathed with beta-particles whose short range in tissues spares the surrounding normal structures. This article will review the rationale, physiology, and patient selection criteria for its use. Approximately 80% of patients will respond to treatment as documented by the authors experience and by a review of the literature.
Soffen
E M
EM
Department of Radiation Oncology, Medical Center of Princeton, NJ 08542, USA.
Greenberg
A
A
Baumann
J
J
Corn
B W
BW
D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000556:secondary*; D018849:Controlled Clinical Trials as Topic; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010166:Palliative Care; D018579:Patient Selection; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000473:pathology*; D013326:Strontium Radioisotopes / Q000008:administration & dosage*; D015996:Survival Rate
D013326:Strontium Radioisotopes